Phytosterols for Cardiovascular Disease

Verdict: Lowers cholesterol, but heart benefit unproven

Phytosterols reliably lower LDL cholesterol, but no adequately powered trial has shown they actually reduce heart attacks, strokes, or cardiovascular deaths, and recent genetic studies even hint at possible harm. The evidence for hard cardiovascular outcomes is weak and disputed.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

This grade reflects a sharp gap between surrogate and hard endpoints. A 2025 meta-analysis of 109 randomized trials (PMID 39572895) confirmed phytosterols lower LDL-C by about 12.57 mg/dL, but it measured only risk factors, not actual events. A 2021 systematic review (PMID 34468867) was blunt: there is no prospective, placebo-controlled randomized trial testing phytosterols against hard cardiovascular outcomes, so any benefit is inferred, never demonstrated.

The outcome data that do exist are conflicting. A 2012 observational meta-analysis (PMID 22334625, ~11,182 people, industry-funded) found no link between serum plant sterols and cardiovascular disease. But two larger Mendelian randomization studies (PMID 35013273; PMID 37270173, ~667,551 people) found that genetically higher blood sitosterol raised coronary atherosclerosis (OR 1.52) and myocardial infarction (OR 1.40) risk, a signal pointing toward harm rather than protection.

Authorities split along the same surrogate-versus-outcome line. The US FDA permits a health claim that plant sterol esters 'may reduce the risk of heart disease,' but this rests on LDL lowering, not event trials. The UK's NICE explicitly advises clinicians not to recommend plant sterols or stanols to prevent CVD, and the Mayo Clinic notes it is 'not clear whether' they lower heart attack or stroke risk. WHO/JECFA addresses only safety, not efficacy. Hence a Weak, Disputed rating.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.49

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

C · Disputed

Confidence

68%

Broadly consistent

Evidence level

Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive

L2 PubMedPrimary literature

0.45

L3 MechanismPlausibility

0.45

L1 ExamineGlobal benchmark

0.50

L11 AI re-checkIndependent read

0.50

L5 Clinical bodiesAuthoritative stance

0.58

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.493
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
tier_strict_requirement_check — Tier 條件達標，未降階
detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Genome-wide meta-analysis of phytosterols reveals five novel loci and a detrimental effect on coronary atherosclerosis

PMID: 35013273 2022 統合分析 n = 9,758

Finding: This genome-wide meta-analysis (up to 9,758 subjects, 32 phytosterol traits) plus Mendelian randomization found a risk-INCREASING causal effect of higher plasma sitosterol on CAD (total causal estimate 0.308, SE 0.065, p=1.9x10^-6). A direct effect of sitosterol itself accounted for 53% of the total effect (0.163, SE 0.072, p=0.023), with the remainder mediated by cholesterol (0.145, SE 0.031, p=2.2x10^-6) — suggesting plant sterols per se may be atherogenic, not protective.

Government Effect size: [object Object]

View on PubMed

Blood phytosterols in relation to cardiovascular diseases and mediating effects of blood lipids and hematological traits: a Mendelian randomization analysis

PMID: 37270173 2023 Other n = 667,551

Finding: Mendelian randomization found that a one-unit increment in log-transformed blood total sitosterol was significantly associated with higher risk of coronary atherosclerosis (OR 1.52; 95% CI 1.41-1.65; n=667,551) and myocardial infarction (OR 1.40; 95% CI 1.25-1.56; n=596,436). Blood non-HDL-C and apolipoprotein B mediated roughly 38-60% of these associations, indicating elevated serum phytosterols are linked to greater CVD risk.

Effect size: [object Object]

View on PubMed

Effects of phytosterols on cardiovascular risk factors: A systematic review and meta-analysis of randomized controlled trials

PMID: 39572895 2025 統合分析

Finding: This meta-analysis of 109 RCTs found phytosterols significantly lowered LDL-C (mean difference -12.57 mg/dL; 95% CI -13.87 to -11.26; p<0.001), total cholesterol (-13.41) and triglycerides (-6.34), and slightly raised HDL-C (+0.46). Critically, only surrogate risk factors were assessed — hard cardiovascular events (MACE, MI, mortality) were NOT evaluated, so LDL lowering cannot be equated with proven CV benefit.

Government Effect size: [object Object]

View on PubMed

Plant sterols and cardiovascular disease: a systematic review and meta-analysis

PMID: 22334625 2012 統合分析 n = 11,182

Finding: This meta-analysis of 17 observational studies (11,182 participants; case-control, cohort, cross-sectional and nested case-control) found NO association between serum plant sterol levels and CVD risk: campesterol RR 1.02 (95% CI 0.94-1.09, p=0.675) and sitosterol/cholesterol ratio RR 0.94 (95% CI 0.68-1.31, p=0.730). This contrasts with later Mendelian randomization data and is industry-funded, underscoring the unsettled outcome picture.

🟠 Limited quality ⚠️ Industry-funded Effect size: [object Object]

View on PubMed

Phytosterols and Cardiovascular Disease

PMID: 34468867 2021 系統性回顧

Finding: This review concludes phytosterols lower LDL-C by 10-15%, but states there is no prospective, placebo-controlled, randomized trial addressing the impact of phytosterol supplementation on hard cardiovascular outcomes. It notes recent genetic evidence suggesting plant sterols per se are atherogenic, with non-HDL cholesterol explaining only ~60% of the associated CVD risk increase, and explicitly calls for RCTs with hard CV outcomes before any general recommendation.

Effect size: LDL-C reduction 10-15%; no hard CV outcome trial exists

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA

Supportive

Foods containing at least 0.65 g per serving of plant sterol esters, eaten twice a day with meals for a daily total intake of at least 1.3 g, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease. source↗

L4b EU EFSA

Supportive

L4c UK NHS

Against

Do not advise any of the following to take plant stanols or sterols to prevent CVD: people being treated for primary prevention; people being treated for secondary prevention; people with CKD; people with type 1 diabetes; people with type 2 diabetes. [2014] source↗

L4d TW TFDA / 衛福部

Supportive

市售有兩款添加植醇的植物油（透過衛福部審核通過之健康食品資料庫）。每日攝取2到3克的植物固醇，對於降低血中的總膽固醇與低密度脂蛋白膽固醇（壞的膽固醇）都有顯著的幫助。 source↗

L4e WHO

Neutral

JECFA established a group acceptable daily intake (ADI) of 0-40 mg/kg body weight for phytosterols, phytostanols and their esters, expressed as the sum of phytosterols and phytostanols in their free form, based on an overall NOAEL of 4200 mg/kg bw per day to which a safety factor of 100 was applied. source↗

L5a NIH Office of Dietary Supplements

Cautious

L5b Mayo Clinic

Neutral

Adding 2 grams of sterol to your diet every day can lower your LDL cholesterol by 5% to 15%. However, it's not clear whether food with plant sterols or stanols lowers your risk of heart attack or stroke — although experts assume that foods that lower cholesterol do cut the risk. source↗

L5c Cleveland Clinic

Supportive

L5d Harvard Health

Cautious

L5e Specialty Society (condition-mapped)

Neutral

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬5 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-cardiovascular-disease-INT-phytosterols-001 繁體中文版 →